AMS2392

**AMS2392** is a proprietary oral essential-amino-acid nutritional formulation developed by The Amino Company for reduction of hepatic steatosis and associated cardiometabolic risk. The formulation contains histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine. It is being evaluated as a medical-nutrition intervention in children with metabolic dysfunction-associated steatotic liver disease. Proposed metabolic effects include reduced hepatic de novo lipogenesis, increased hepatic and systemic fatty-acid oxidation, and increased hepatic triglyceride export; no discrete molecular drug target has been publicly specified. ([ctv.veeva.com](https://ctv.veeva.com/study/smart-diets-for-masld))

Other names

EAAessential amino acid supplement